Damijan Knez

Medicine · Health Sciences

28h-index2.3kcitations109works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholinesterase and Neurodegenerative Diseases(59), Computational Drug Discovery Methods(52), Alzheimer's disease research and treatments(16), Chemical synthesis and alkaloids(16), Click Chemistry and Applications(12)

Publications109 total

Katepsina B in X pri tumorskih matičnih celicah
DiRROS repository (University of Maribor)·2026
Expanding the reactive chemistry toolbox – warhead screening for covalent butyrylcholinesterase inhibitors
Chemico-Biological Interactions·2025Open Access
Dual cholinergic modulation in dementia: Quinuclidine carbamates targeting butyrylcholinesterase and α7 nicotinic receptor
Chemico-Biological Interactions·2025Open Access
N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d]imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer’s disease
Biomedicine & Pharmacotherapy·2025Open Access
Transforming ureas into carbamates: From allosteric p38α MAPK ligands to dual BChE/p38α MAPK inhibitors
Bioorganic Chemistry·2025Open Access
Tunable nucleofugality in carbamoyl-bearing covalent cholinesterase inhibitors
2025Open Access
Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors
Journal of Medicinal Chemistry·2025· 2 citedOpen Access
N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors
Chemico-Biological Interactions·2025· 1 citedOpen Access
Chiral switch of a butyrylcholinesterase inhibitor for the treatment of Alzheimer's disease
Chemico-Biological Interactions·2025· 1 citedOpen Access
Pleiotropic prodrugs for both symptomatic and disease-modifying treatment of Alzheimer’s disease
Acta Pharmaceutica Sinica B·2025Open Access
Lead Optimization of a Butyrylcholinesterase Inhibitor for the Treatment of Alzheimer’s Disease
Journal of Medicinal Chemistry·2025· 5 citedOpen Access
α-Heteroarylthiomethyl ketones: Small molecule inhibitors of 3CL <sup>pro</sup>
Acta Pharmaceutica·2025Open Access
Biochemical characteristics of the 6-nitro regioisomer of nitroxoline and its 1,2,3,4-tetrahydroquinoline analogues
Acta Pharmaceutica·2025· 1 citedOpen Access
Facile Synthesis of Carbamoyl Fluorides <i>via</i> <i>N</i>-Carbamoylimidazole Activation
ACS Omega·2025· 2 citedOpen Access
Access to amidines <i>via</i> C(sp<sup>2</sup>)–N coupling of trifluoroborate-iminiums with <i>N</i>-fluorobenzenesulfonimide
Chemical Science·2025· 4 citedOpen Access
Contilistat, a New Multitarget Small Polyfunctionalized Indole Derivative
Synlett·2024· 2 citedOpen Access
Azide- and Transition-Metal-Free Access to Sulfonyl Amidines via C(sp2)-N Coupling of Trifluoroborate-Iminiums with N-Fluorobenzenesulfonimide
2024Open Access
Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease
Pharmacology & Therapeutics·2024· 8 citedOpen Access
Development of novel aza-stilbenes as a new class of selective MAO-B inhibitors for the treatment of Parkinson’s disease
Bioorganic Chemistry·2024Open Access
Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with <i>In Vitro</i> and <i>In Vivo</i> Activity in Neurodegenerative Diseases
Journal of Medicinal Chemistry·2024· 18 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Stanislav Gobec(49), Janko Kos(16), Anja Pišlar(15), Xavier Brazzolotto(15), Barbara Malawska(13), Anna Więckowska(12), Justyna Godyń(12), Florian Nachon(11), Izidor Sosič(9), Simon Žakelj(8), Tomasz Wichur(8), Urban Košak(7), Boris Brus(7), Dawid Panek(7), Jure Stojan(6), Nicolas Coquelle(6), Jacques‐Philippe Colletier(6), Anna Pasieka(6), Kinga Sałat(5), Marko Jukič(5)